Join us for CMT’s largest and most engaging global convention, bringing together the scientific community and patients in a single event.

The CMT Research Foundation is laser-focused on delivering treatments and cures for Charcot-Marie-Tooth disease during our lifetime.

The 2022 Global CMT Research Convention will gather researchers, pharmaceutical companies, biotech companies, government and patients to discuss and find solutions for the most pressing problems in CMT research.

Come learn what the future holds for CMT research and how you can help end this disease!

For the Scientific Community

September 16th

A day for researchers, industry and government agencies to:

SHARE the latest in CMT drug development research

CREATE new connections and collaborations

EXAMINE the most pressing issues facing CMT drug development

Featured speaker: Chris Austin, Flagship Pioneering 


Click here to see the full day of event agenda

TBD by April 15th

Keynote Speaker

Robert "Bob" Baloh, MD, PhD



Zarife Sahenk, MD, PhD

Nationwide Children’s Hospital

United States

Kleopas Kleopa, MD

Cyprus Institute of Neurology & Genetics


For the Patient Community

September 17th

A day for the patient community to:

LEARN about the latest CMT research developments and clinical trials

INTERACT with distinguished scientific experts

ACT to speed treatments for patients and families


A salute to the achievements and pioneers that have paved the way towards a cure and preview the work to come that will end CMT once and for all.


Click here to see the full day of event agenda

TBD by April 15th

Keynote Speaker

Amanda Haidet-Phillips, PhD

Novartis Gene Therapies

United States

David Herrmann, MBBCh

University of Rochester

United States

William Motley, MD, DPhil

Flare Therapeutics

United States

If you have any questions please contact Vanessa Sanchez at [email protected] or +1 (404) 474-8805

Thank You to Our Sponsors!

The Scientific Programming Committee

Marina Kennerson, PhD

Professor of Neurogenetics and Neuroscience

ANZAC Research Institute and University of Sydney, Australia

Charles Abrams, MD, PhD

Professor of Neurology and Rehabilitation

University of Illinois, Chicago (UIC)

Edritz Javelosa, PhD

Research Portfolio Director 

Muscular Dystrophy Association

Paul August, PhD

Vice President, Biology Department Head & Preclinical GDD Portfolio Leader

Agios Pharmaceuticals

Amanda Haidet-Phillips, PhD

Senior Director, Translational Medicine

Novartis Institutes for BioMedical Research

Dennis Klein, PhD

Research Scientist, Department of Neurology

University Hospital Wuerzburg, Germany

Glen Nuckolls, PhD

Program Director, Neurogenetics, Division of Neuroscience

U.S. National Institute of Neurological Disorders and Stroke (NINDS)

Tiina Urv, PhD

Program Director, Office of Rare Diseases Research

U.S. National Center for Advancing Translational Sciences (NCATS)

Alessandra Bolino, PhD

Group Leader, Human Inherited Neuropathies Unit 

San Raffaele Scientific Institute, Milan, Italy